Trials / Active Not Recruiting
Active Not RecruitingNCT06113471
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | Oral, Tablet |
| DRUG | Placebo | Oral, Tablet |
Timeline
- Start date
- 2023-11-27
- Primary completion
- 2026-03-17
- Completion
- 2027-03-16
- First posted
- 2023-11-02
- Last updated
- 2026-03-31
Locations
86 sites across 9 countries: United States, Bulgaria, Canada, France, Germany, Hungary, Italy, Poland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06113471. Inclusion in this directory is not an endorsement.